CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Quinine plus sulfadoxine-pyrimethaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00167739
NCT00167739Phase 4Completed
CompareCT.gov

Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria

Albert Schweitzer Hospital·interventional·Posted Sep 14, 2005·Updated Sep 21, 2005

In Brief

A Phase 4 clinical trial evaluating Quinine plus sulfadoxine-pyrimethamine for Malaria. Completed, across 1 site.

Detailed Summary

Quinine remains the treatment of choice of hospitalised malaria cases. The long treatment duration of 7 days, and adverse reactions often hamper its adequate use. Reducing the treatment duration by adding sulfadoxine-pyrimethamine may enhance compliance and reduce side effects. The efficacy of a 3-day treatment of quinine plus sulfadoxine-pyrimethamine for the treatment of hospitalised, uncomplicated malaria cases was assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesGabon
Collaborators--

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 14, 2005
Enrollment StartApr 1, 2003
Study CompletionFeb 1, 2004
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Quinine plus sulfadoxine-pyrimethaminedrug